MATRIX: Bivalirudin Reduced Mortality vs UFH in ACS Setting

On its primary MACE end point, the MATRIX study missed in showing the superiority of bivalirudin over unfractionated heparin in ACS patients undergoing PCI, but mortality and bleeding advantages were observed.

Heartwire from Medscape

via Medscape news